Objective To assess the predictive value of Glasgow Prognostic Score ( GPS) system for mortality in patients with acute-on-chronic liver failure associated with hepatitis B ( HBV-ACLF) . Methods The clinical data of 437 patients who were diagnosed with HBV-ACLF and admitted to the Department of Infectious Diseases, The First Affiliated Hospital of Xinjiang Medical University, from April 2008 to April 2012 were retrospectively evaluated. Patients were grouped according to their GPS scores, and the mortality rates were compared between GPS groups. Continuous data in normal distribution were compared by t test between two groups and by F-test between three or more groups. Comparison of categorical data was made by chi-square test. COX proportional hazards regression was performed to identify clinical variables associated with overall survival during the follow-up period [30 ( 5-825) d]. Results The mortality rate of patients with HBV-ACLF was 68. 0% ( 297 cases) during the follow-up period. The group with higher GPS scores had significantly increased proportions of individuals with gastrointestinal bleeding, hepatic encephalopathy, and hepatorenal syndrome and higher Model of End-Stage Liver Disease scores ( P < 0. 05 across all variables) . COX proportional hazards regression analysis revealed the risk factors closely associated with the mortality of patients with HBV-ACLF, which included hepatic encephalopathy ( grade I-II vs absence of hepatic encephalopathy: hazard ratio, HR: 2. 520, 95% confidence interval, CI: 1. 479-4. 293, P = 0. 001; grade III-IV vs absence of hepatic encephalopathy: HR:3. 678, 95% CI: 1. 920-7. 047, P < 0. 001) , hepatorenal syndrome ( HR: 2. 374, 95% CI: 1. 452-3. 881, P = 0. 001) , gastrointestinal bleeding ( HR: 1. 616, 95% CI: 1. 153-2. 262, P = 0. 004) , antiviral therapy ( HR: 0. 668, 95% CI: 0. 518-0. 862, P = 0. 002) and the GPS ( 1 vs 0: HR: 2. 055, 95% CI: 1653-2. 702, P = 0. 001; 2 vs 0: HR: 4. 520, 95% CI: 3. 288-6. 932, P = 0. 007) . Conclusion The GPS system has a good predictive value for short-and long-term mortality in patients with HBV-ACLF. Elevated GPS is an independent risk factor for death in patients with chronic liver failure associated with hepatitis B.
[1]HE HL, LI JG, GAO ZL, et al.Investigation of artificial liver support system combined with stem cell transplantation in treatment of liver failure[J].J Clin Hepatol, 2013, 29 (9) :670-673. (in Chinese) 何宏亮, 李建国, 高志良, 等.人工肝和干细胞在肝衰竭治疗中的进展[J].临床肝胆病杂志, 2013, 29 (9) :670-673.
|
[2]KINOSHITA A, ONODA H, IMAI N, et al.The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma[J].BMC Cancer, 2013, 13:52.
|
[3]PIERI G, AGARWAL B, BURROUGHS AK.C-reactive protein and bacterial infection in cirrhosis[J].Ann Gastroenterol, 2014, 27 (2) :113-120.
|
[4]SINGH PP, ZENG IS, SRINIVASA S, et al.Systematic review and meta-analysis of use of serum C-reactive protein levels to predict anastomotic leak after colorectal surgery[J].Br J Surg, 2014, 101 (4) :339-346.
|
[5]RIETZSCHEL de, DE BUYZERE M.High-sensitive C-reactive protein:universal prognostic and causative biomarker in heart disease?[J].Biomark Med, 2012, 6 (1) :19-34.
|
[6]MCMILLAN DC.An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer[J].Proc Nutr Soc, 2008, 67 (3) :257-262.
|
[7]MCMILLAN DC.The systemic inflammation-based Glasgow Prognostic Score:a decade of experience in patients with cancer[J].Cancer Treat Rev, 2013, 39 (5) :534-540.
|
[8]KAPTOGE S, SESHASAI SR, GAO P, et al.Inflammatory cytokines and risk of coronary heart disease:new prospective study and updated meta-analysis[J].Eur Heart J, 2014, 35 (9) :578-589.
|
[9]SILVESTRE JP, COELHO LM, PóVOA PM.Impact of fulminant hepatic failure in C-reactive protein?[J].J Crit Care, 2010, 25 (4) :657.e7-e12.
|
[10]CERVONI JP, THEVENOT T, WEIL D, et al.C-reactive protein predicts short-term mortality in patients with cirrhosis[J].J Hepatol, 2012, 56 (6) :1299-1304.
|